Twist Bioscience Co. (NASDAQ:TWST) SVP Sells $45,400.41 in Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 1,137 shares of Twist Bioscience stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $39.93, for a total transaction of $45,400.41. Following the completion of the transaction, the senior vice president now directly owns 88,837 shares in the company, valued at approximately $3,547,261.41. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Paula Green also recently made the following trade(s):

• On Tuesday, July 2nd, Paula Green sold 322 shares of Twist Bioscience stock. The stock was sold at an average price of $48.00, for a total transaction of $15,456.00.
• On Thursday, June 20th, Paula Green sold 297 shares of Twist Bioscience stock. The shares were sold at an average price of $49.41, for a total value of $14,674.77.
• On Thursday, June 6th, Paula Green sold 918 shares of Twist Bioscience stock. The stock was sold at an average price of $51.33, for a total value of $47,120.94.

Twist Bioscience Price Performance

TWST traded down $1.45 on Friday, reaching $43.97. 944,659 shares of the company traded hands, compared to its average volume of 1,050,882. Twist Bioscience Co. has a 52-week low of $14.42 and a 52-week high of $60.90. The company has a market cap of $2.58 billion, a price-to-earnings ratio of -13.09 and a beta of 1.80. The stock’s 50 day moving average price is $50.93 and its 200-day moving average price is $41.70.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The company had revenue of $81.50 million during the quarter, compared to analyst estimates of $77.40 million. During the same period last year, the company posted ($1.01) earnings per share. The company’s revenue was up 27.7% compared to the same quarter last year. As a group, equities research analysts forecast that Twist Bioscience Co. will post -3.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Twist Bioscience

Large investors have recently made changes to their positions in the company. BNP Paribas Financial Markets raised its position in Twist Bioscience by 34.8% during the first quarter. BNP Paribas Financial Markets now owns 171,823 shares of the company’s stock valued at $5,895,000 after acquiring an additional 44,349 shares in the last quarter. UBS Group AG lifted its stake in shares of Twist Bioscience by 106.4% in the 4th quarter. UBS Group AG now owns 213,467 shares of the company’s stock valued at $7,868,000 after purchasing an additional 110,036 shares during the last quarter. Nikko Asset Management Americas Inc. boosted its holdings in Twist Bioscience by 2.9% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 3,583,443 shares of the company’s stock worth $131,835,000 after purchasing an additional 99,511 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in Twist Bioscience during the first quarter worth $300,000. Finally, SageView Advisory Group LLC bought a new position in Twist Bioscience during the first quarter valued at about $1,144,000.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Scotiabank boosted their target price on Twist Bioscience from $43.00 to $48.00 and gave the stock a “sector outperform” rating in a research report on Monday, May 6th. Robert W. Baird upped their price objective on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research note on Monday, August 5th. JPMorgan Chase & Co. lifted their target price on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research report on Monday, August 5th. TD Cowen boosted their price target on shares of Twist Bioscience from $55.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, June 13th. Finally, The Goldman Sachs Group raised their price objective on shares of Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, July 9th. One analyst has rated the stock with a sell rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $48.22.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.